• GBC cut Bio-Gate’s price target to EUR 13.65, maintaining its Buy rating in a Nov. 2, 2026, research update.
• The target, set for Dec. 31, 2027, compares with EUR 17 adjusted for the 5-for-1 share consolidation.
• Lower forecasts and a higher risk-free interest rate drove the target reduction.
• GBC lowered its 2026 revenue forecast to EUR 6.2 million from EUR 7.4 million; it expects an operating recovery from 2027.
• The analysts forecast positive EBITDA of EUR 490,000 in 2028, contingent on the recovery and sustained efficiency improvements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Gate AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27268) on November 02, 2026, and is solely responsible for the information contained therein.